Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Neurother. 2014 Apr;14(4):379-88. doi: 10.1586/14737175.2014.890891. Epub 2014 Feb 19.

Potential of glyburide to reduce intracerebral edema in brain metastases.

Author information

1
Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD 21201, USA.

Abstract

Metastatic disease to the brain results in significant morbidity because of edema in the central nervous system. Current anti-edema therapies are either expensive or result in unwanted long-term side effects. Sulfonylurea receptor 1 (Sur1) is a transmembrane protein that, when activated in the central nervous system, allows for unregulated sodium influx into cells, a process that has been linked to cytotoxic edema formation in ischemic stroke, subarachnoid hemorrhage, spinal cord injury, traumatic brain injury, and, most recently, brain metastases. In this focused review, we explore preclinical data linking Sur1 channel formation to development of edema and reference evidence suggesting that the antidiabetic sulfonylurea drug glyburide (a Sur1 inhibitor) is an inexpensive and well-tolerated agent that can be clinically tested to reduce or prevent malignancy and/or treatment-associated edema.

PMID:
24552576
DOI:
10.1586/14737175.2014.890891
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center